Jefferies Group's position in Axsome Therapeutics is currently worth $25.5 Million. That's 0.57% of their equity portfolio (36th largest holding). Jefferies Group started to build up the position in Axsome Therapeutics in Q3 2023 and continued to invest until Q4 2023. Since then they sold 231 Thousand shares. The stake costed the investor $24.8 Million, netting the investor a gain of 2.6% so far.
NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class ac...
GlobeNewswire, almost 2 years agoGoldman Sachs Group Inc. lowered its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 70.5% during the second quarter, according to its most recent Form 1...
Dakota Financial News, over 2 years agoMan Group plc trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 80.9% during the second quarter, Holdings Channel reports. The fir...
Dakota Financial News, over 2 years ago